Cargando…
TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS)
SIMPLE SUMMARY: T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) acts as an immune checkpoint on exhausted T cells and has been associated with dismal outcomes in various solid tumors. TIM3 is currently being evaluated as an immunotherapeutic target in multiple clinical trials. Ou...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216414/ https://www.ncbi.nlm.nih.gov/pubmed/37345075 http://dx.doi.org/10.3390/cancers15102735 |